[{"id":"6e8c9c85-9d26-4c35-8860-c80648e49b52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02188264","created_at":"2021-01-18T10:12:45.005Z","updated_at":"2025-02-25T15:25:18.307Z","phase":"Phase 1","brief_title":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02188264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • RAF1 • MAPK1","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • RAF1 • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/29/2014","start_date":" 08/29/2014","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 04/26/2019","study_completion_date":" 04/26/2019","last_update_posted":"2025-02-11"},{"id":"a0cf279a-8d5c-46c3-9bca-6f57de2820c1","acronym":"NAUTICALCRC","url":"https://clinicaltrials.gov/study/NCT05004350","created_at":"2021-08-13T12:53:27.664Z","updated_at":"2025-02-25T16:16:36.860Z","phase":"Phase 2","brief_title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT05004350 - NAUTICALCRC","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type","tags":["BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/19/2023","primary_completion_date":" 12/19/2023","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-06-18"},{"id":"77cb581e-c173-4f2c-a06e-c96db7736264","acronym":"RAS-HEMATO","url":"https://clinicaltrials.gov/study/NCT04286360","created_at":"2021-01-18T20:48:27.393Z","updated_at":"2024-07-02T16:34:59.177Z","phase":"","brief_title":"Hematological Anomalies in Children With Rasopathy","source_id_and_acronym":"NCT04286360 - RAS-HEMATO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1","pipe":" | ","alterations":" BRAF mutation • CBL mutation • MAP2K1 mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • CBL mutation • MAP2K1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-06-04"},{"id":"f8142c0b-7e40-45b9-aed0-5a10b17b3a25","acronym":"FIRELIGHT-1","url":"https://clinicaltrials.gov/study/NCT04985604","created_at":"2023-06-26T16:09:30.280Z","updated_at":"2024-07-02T16:35:12.349Z","phase":"Phase 1/2","brief_title":"Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT04985604 - FIRELIGHT-1","lead_sponsor":"Day One Biopharmaceuticals, Inc.","biomarkers":" BRAF • NF1 • RAF1","pipe":" | ","alterations":" BRAF fusion • RAF1 amplification","tags":["BRAF • NF1 • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF fusion • RAF1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib) • pimasertib (AS703026)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-29"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"d6f097ba-9519-4376-8dfc-112499960700","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840409","created_at":"2021-01-18T13:56:34.086Z","updated_at":"2024-07-02T16:35:21.598Z","phase":"Phase 2","brief_title":"Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)","source_id_and_acronym":"NCT02840409","lead_sponsor":"The Hospital for Sick Children","biomarkers":" BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1","pipe":" | ","alterations":" BRAF mutation • FGFR1 fusion","tags":["BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • FGFR1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-01-31"},{"id":"58b26f64-7b26-4c99-ba89-84483413fd67","acronym":"","url":"https://clinicaltrials.gov/study/NCT02367859","created_at":"2021-01-18T11:16:38.843Z","updated_at":"2025-02-25T15:42:16.020Z","phase":"Phase 2","brief_title":"Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma","source_id_and_acronym":"NCT02367859","lead_sponsor":"Stanford University","biomarkers":" ALK • RAF1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["ALK • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 11/05/2018","primary_completion_date":" 11/05/2018","study_txt":" Completion: 06/26/2019","study_completion_date":" 06/26/2019","last_update_posted":"2024-01-30"},{"id":"20481648-b24a-4001-9d26-bf1b3e73c61c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451553","created_at":"2021-01-18T11:45:16.896Z","updated_at":"2024-07-02T16:36:09.285Z","phase":"Phase 1","brief_title":"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer","source_id_and_acronym":"NCT02451553","lead_sponsor":"University of Washington","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • CDH1 • RAF1 • RAS","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDH1 expression • CDH1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • CDH1 • RAF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDH1 expression • CDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 04/16/2022","primary_completion_date":" 04/16/2022","study_txt":" Completion: 04/16/2022","study_completion_date":" 04/16/2022","last_update_posted":"2022-06-07"},{"id":"4e5f3a4f-056a-4b8c-8cf7-2b1b82c0f75c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02263898","created_at":"2021-01-18T10:38:18.015Z","updated_at":"2024-07-02T16:36:42.741Z","phase":"Phase 2","brief_title":"Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations","source_id_and_acronym":"NCT02263898","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" RAF1","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-07-27"},{"id":"91ad3d38-3b0f-422a-86a7-7efdaddf4872","acronym":"","url":"https://clinicaltrials.gov/study/NCT02455245","created_at":"2021-01-18T11:46:43.065Z","updated_at":"2024-07-02T16:37:12.801Z","phase":"Phase 3","brief_title":"A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma","source_id_and_acronym":"NCT02455245","lead_sponsor":"Natasha Pillay Smiley","biomarkers":" BRAF • RAF1","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • RAF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • vincristine"],"overall_status":"Unknown status","enrollment":" Enrollment 160","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2018-03-26"}]